A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
J Skat‐Rørdam, D Højland Ipsen… - Basic & clinical …, 2019 - Wiley Online Library
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …
increases and there are no approved treatment options. Thiazolidinediones target the …
[PDF][PDF] A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
J Skat‐Rørdam, DH Ipsen, J Lykkesfeldt… - Basic Clin Pharmacol …, 2019 - core.ac.uk
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …
increases and there are no approved treatment options. Thiazolidinediones target the …
[引用][C] A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
J Skat‐Rørdam, DH Ipsen, J Lykkesfeldt… - Basic & Clinical …, 2019 - cir.nii.ac.jp
A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease.
J Skat-Rørdam, J Lykkesfeldt… - Basic & Clinical …, 2019 - europepmc.org
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …
increases and there are no approved treatment options. Thiazolidinediones target the …
A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease
J Skat-Rørdam, DH Ipsen… - Basic & clinical …, 2019 - pubmed.ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …
increases and there are no approved treatment options. Thiazolidinediones target the …
A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease.
J Skat‐Rørdam, D Højland Ipsen… - Basic & Clinical …, 2019 - search.ebscohost.com
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …
increases and there are no approved treatment options. Thiazolidinediones target the …
[HTML][HTML] A role of peroxisome proliferator‐activated receptor γ in non‐alcoholic fatty liver disease
J Skat‐Rørdam, DH Ipsen, J Lykkesfeldt… - Basic & Clinical …, 2019 - ncbi.nlm.nih.gov
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …
increases and there are no approved treatment options. Thiazolidinediones target the …
A role of peroxisome proliferator-activated receptor γ in non-alcoholic fatty liver disease.
J Skat-Rørdam, J Lykkesfeldt… - Basic & Clinical …, 2019 - europepmc.org
Non‐alcoholic fatty liver disease is becoming a major health burden, as prevalence
increases and there are no approved treatment options. Thiazolidinediones target the …
increases and there are no approved treatment options. Thiazolidinediones target the …